Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lyell Immunopharma (LYEL) Net Cash Flow (2020 - 2025)

Lyell Immunopharma's Net Cash Flow history spans 6 years, with the latest figure at $24.8 million for Q3 2025.

  • For Q3 2025, Net Cash Flow rose 174.79% year-over-year to $24.8 million; the TTM value through Sep 2025 reached $24.6 million, up 113.22%, while the annual FY2024 figure was -$38.6 million, 274.88% down from the prior year.
  • Net Cash Flow for Q3 2025 was $24.8 million at Lyell Immunopharma, up from -$21.6 million in the prior quarter.
  • Across five years, Net Cash Flow topped out at $320.1 million in Q2 2021 and bottomed at -$170.9 million in Q3 2021.
  • The 5-year median for Net Cash Flow is -$14.1 million (2023), against an average of -$826947.4.
  • The largest YoY upside for Net Cash Flow was 781.89% in 2023 against a maximum downside of 2040.45% in 2023.
  • A 5-year view of Net Cash Flow shows it stood at -$99.7 million in 2021, then surged by 107.27% to $7.2 million in 2022, then plummeted by 2040.45% to -$140.6 million in 2023, then soared by 104.77% to $6.7 million in 2024, then soared by 269.73% to $24.8 million in 2025.
  • Per Business Quant, the three most recent readings for LYEL's Net Cash Flow are $24.8 million (Q3 2025), -$21.6 million (Q2 2025), and $14.7 million (Q1 2025).